Literature DB >> 10590101

Mutations in the 5' trailer region of a respiratory syncytial virus minigenome which limit RNA replication to one step.

M E Peeples1, P L Collins.   

Abstract

The 3' termini of the genomic and antigenomic RNAs of human respiratory syncytial virus (RSV) are identical at 10 of the first 11 nucleotide positions and 21 of the first 26 positions. These conserved 3'-terminal sequences are thought to contain the genomic and antigenomic promoters. Furthermore, the complement of each conserved sequence (i.e., the 5' end of the RNA it encodes) might contain an encapsidation signal. Using an RSV minigenome system, we individually mutated each of the last seven nucleotides in the 5' trailer region of the genome. We analyzed effects of these mutations on encapsidation of the T7 polymerase-transcribed negative-sense genome, its ability to function as a template for RSV-driven synthesis of positive-sense antigenome and mRNA, and the ability of this antigenome to be encapsidated and to function as template for the synthesis of more genome. As a technical complication, mutations in the last five nucleotides of the trailer region were found to affect the efficiency of the adjoining T7 promoter over more than a 10-fold range, even though three nonviral G residues had been included between the core promoter and the trailer to maximize the efficiency of promoter activity. This was controlled in all experiments by monitoring the levels of total and encapsidated genome. The efficiency of encapsidation of the T7 polymerase-transcribed genome was not affected by any of the trailer mutations. Furthermore, neither the efficiency of positive-sense RNA synthesis from the genome nor the efficiency of encapsidation of the encoded antigenome was affected by the mutations. However, nucleotide substitution at positions 2, 3, 6, or 7 relative to the 5' end of the trailer blocked the production of progeny genome, whereas substitution at positions 1 and 5 allowed a low level of genome production and substitutions at position 4 were tolerated. Position 4 is the only one of the seven positions examined that is not conserved between the 3' ends of genomic and antigenomic RNA. The mutations that blocked the synthesis of progeny genome thus limited RNA replication to one step, namely, the synthesis and encapsidation of antigenome. Restoration of terminal complementarity for one of the trailer mutants by making a compensatory mutation in the leader region did not restore synthesis of genomic RNA, confirming that its loss was not due to reduced terminal complementarity. Interestingly, this leader mutation appeared to prevent antigenome synthesis with only a slight effect on mRNA synthesis, apparently providing a dissociation between these two synthetic activities. Genomes in which the terminal 24 or 325 nucleotides of the trailer have been deleted were competent for encapsidation and the synthesis of mRNA and antigenomic RNA, further confirming that terminal complementarity was not required for these functions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10590101      PMCID: PMC111523          DOI: 10.1128/jvi.74.1.146-155.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  A pseudoknot-like structure required for efficient self-cleavage of hepatitis delta virus RNA.

Authors:  A T Perrotta; M D Been
Journal:  Nature       Date:  1991-04-04       Impact factor: 49.962

2.  Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase.

Authors:  T R Fuerst; E G Niles; F W Studier; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

3.  Nucleotide sequences of the 3' leader and 5' trailer regions of human respiratory syncytial virus genomic RNA.

Authors:  M A Mink; D S Stec; P L Collins
Journal:  Virology       Date:  1991-12       Impact factor: 3.616

4.  Encapsidation of Sendai virus genome RNAs by purified NP protein during in vitro replication.

Authors:  S C Baker; S A Moyer
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

5.  Bacteriophage T7 late promoters with point mutations: quantitative footprinting and in vivo expression.

Authors:  K A Chapman; S I Gunderson; M Anello; R D Wells; R R Burgess
Journal:  Nucleic Acids Res       Date:  1988-05-25       Impact factor: 16.971

6.  N protein of vesicular stomatitis virus selectively encapsidates leader RNA in vitro.

Authors:  B M Blumberg; C Giorgi; D Kolakofsky
Journal:  Cell       Date:  1983-02       Impact factor: 41.582

7.  Role of the M2-1 transcription antitermination protein of respiratory syncytial virus in sequential transcription.

Authors:  R Fearns; P L Collins
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

8.  Tubulin: a factor necessary for the synthesis of both Sendai virus and vesicular stomatitis virus RNAs.

Authors:  S A Moyer; S C Baker; J L Lessard
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

9.  Oligoribonucleotide synthesis using T7 RNA polymerase and synthetic DNA templates.

Authors:  J F Milligan; D R Groebe; G W Witherell; O C Uhlenbeck
Journal:  Nucleic Acids Res       Date:  1987-11-11       Impact factor: 16.971

10.  Infectious defective interfering particles of VSV from transcripts of a cDNA clone.

Authors:  A K Pattnaik; L A Ball; A W LeGrone; G W Wertz
Journal:  Cell       Date:  1992-06-12       Impact factor: 41.582

View more
  28 in total

1.  Structural phosphoprotein M2-1 of the human respiratory syncytial virus is an RNA binding protein.

Authors:  I Cuesta; X Geng; A Asenjo; N Villanueva
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  "Rule of six": how does the Sendai virus RNA polymerase keep count?

Authors:  D Vulliémoz; L Roux
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

3.  Characterization of the genomic promoter of the prototypic arenavirus lymphocytic choriomeningitis virus.

Authors:  Mar Perez; Juan Carlos de la Torre
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

4.  Identification of internal sequences in the 3' leader region of human respiratory syncytial virus that enhance transcription and confer replication processivity.

Authors:  David R McGivern; Peter L Collins; Rachel Fearns
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

5.  Evidence that the respiratory syncytial virus polymerase is recruited to nucleotides 1 to 11 at the 3' end of the nucleocapsid and can scan to access internal signals.

Authors:  Vanessa M Cowton; Rachel Fearns
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

6.  Establishment and characterization of plasmid-driven minigenome rescue systems for Nipah virus: RNA polymerase I- and T7-catalyzed generation of functional paramyxoviral RNA.

Authors:  Alexander Freiberg; Lhia Krista Dolores; Sven Enterlein; Ramon Flick
Journal:  Virology       Date:  2007-09-27       Impact factor: 3.616

7.  Evidence that the polymerase of respiratory syncytial virus initiates RNA replication in a nontemplated fashion.

Authors:  Sarah L Noton; Vanessa M Cowton; Chadene R Zack; David R McGivern; Rachel Fearns
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-17       Impact factor: 11.205

8.  Identification and characterization of the binding site of the respiratory syncytial virus phosphoprotein to RNA-free nucleoprotein.

Authors:  Marie Galloux; Gaëlle Gabiane; Julien Sourimant; Charles-Adrien Richard; Patrick England; Mohammed Moudjou; Magali Aumont-Nicaise; Jenna Fix; Marie-Anne Rameix-Welti; Jean-François Eléouët
Journal:  J Virol       Date:  2015-01-07       Impact factor: 5.103

9.  Respiratory Syncytial Virus Inhibitor AZ-27 Differentially Inhibits Different Polymerase Activities at the Promoter.

Authors:  Sarah L Noton; Kartikeya Nagendra; Ewan F Dunn; Michael E Mawhorter; Qin Yu; Rachel Fearns
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

Review 10.  Animal pneumoviruses: molecular genetics and pathogenesis.

Authors:  Andrew J Easton; Joseph B Domachowske; Helene F Rosenberg
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.